Replimune Group Sees Unusually High Options Volume (NASDAQ:REPL)

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) was the target of unusually large options trading activity on Thursday. Traders acquired 5,508 call options on the stock. This is an increase of approximately 652% compared to the typical daily volume of 732 call options.

Replimune Group Trading Up 1.2%

Shares of REPL traded up $0.10 during trading hours on Tuesday, hitting $8.45. 492,882 shares of the stock traded hands, compared to its average volume of 907,474. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. Replimune Group has a 1-year low of $4.92 and a 1-year high of $17.00. The firm has a market capitalization of $650.85 million, a PE ratio of -2.75 and a beta of 0.68. The business has a fifty day moving average of $8.57 and a 200-day moving average of $11.17.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the previous year, the company earned ($0.25) earnings per share. Analysts expect that Replimune Group will post -2.97 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on REPL shares. JPMorgan Chase & Co. lifted their price target on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. HC Wainwright raised their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Replimune Group presently has an average rating of "Buy" and a consensus price target of $19.43.

Insider Transactions at Replimune Group

In other Replimune Group news, CAO Andrew Schwendenman sold 3,287 shares of Replimune Group stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total value of $26,460.35. Following the completion of the transaction, the chief accounting officer now owns 68,284 shares in the company, valued at approximately $549,686.20. The trade was a 4.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Christopher Sarchi sold 3,749 shares of the business's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total value of $30,179.45. Following the completion of the transaction, the insider now directly owns 128,296 shares in the company, valued at approximately $1,032,782.80. This represents a 2.84% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 74,907 shares of company stock valued at $603,655. 8.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Replimune Group

Institutional investors have recently modified their holdings of the business. Sterling Capital Management LLC lifted its holdings in Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after buying an additional 1,655 shares during the period. Graham Capital Management L.P. raised its position in shares of Replimune Group by 6.1% during the 4th quarter. Graham Capital Management L.P. now owns 30,180 shares of the company's stock valued at $365,000 after acquiring an additional 1,731 shares during the last quarter. Deutsche Bank AG lifted its stake in shares of Replimune Group by 0.4% in the 1st quarter. Deutsche Bank AG now owns 563,701 shares of the company's stock valued at $5,496,000 after purchasing an additional 2,140 shares during the period. MetLife Investment Management LLC lifted its stake in shares of Replimune Group by 7.2% in the 4th quarter. MetLife Investment Management LLC now owns 37,659 shares of the company's stock valued at $456,000 after purchasing an additional 2,525 shares during the period. Finally, Arizona State Retirement System boosted its position in shares of Replimune Group by 19.7% in the 1st quarter. Arizona State Retirement System now owns 15,439 shares of the company's stock worth $151,000 after purchasing an additional 2,545 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.